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A B S T R A C T
Background: Low bioavailability of nitric oxide (NO) is implicated in the pathophysiology of sickle cell disease
(SCD). We designed a nested pilot study to be conducted within a clinical trial testing the effects of a daily ready-
to-use supplementary food (RUSF) fortified with arginine (Arg) and citrulline (Citr) vs. non-fortified RUSF in
children with SCD. The pilot study evaluated 1) the feasibility of a non-invasive stable isotope method to
measure whole-body NO production and 2) whether Arg+Citr supplementation was associated with increased
whole-body NO production.
Subjects: Twenty-nine children (70% male, 9–11years, weight 16.3–31.3 kg) with SCD.
Methods: Sixteen children received RUSF+Arg/Citr (Arg, 0.2 g/kg/day; Citr, 0.1 g/kg/day) in combination
with daily chloroquine (50 mg) and thirteen received the base RUSF in combination with weekly chloroquine
(150 mg). Plasma amino acids were assessed using ion-exchange elution (Biochrom-30, Biochrom, UK) and
whole-body NO production was measured using a non-invasive stable isotopic method.
Results: The RUSF+Arg/Citr intervention increased plasma arginine (P = .02) and ornithine (P = .003) and
decreased the ratio of asymmetric dimethylarginine to arginine (P = .01), compared to the base RUSF. A sig-
nificant increase in whole-body NO production was observed in the RUSF-Arg/Citr group compared to baseline
(weight-adjusted systemic NO synthesis 3.38 ± 2.29 μmol/kg/hr vs 2.35 ± 1.13 μmol/kg/hr, P = .04). No
significant changes were detected in the base RUSF group (weight-adjusted systemic NO synthesis
2.64 ± 1.14 μmol/kg/hr vs 2.53 ± 1.12 μmol/kg/hr, P = .80).
Conclusions: The non-invasive stable isotopic method was acceptable and the results provided supporting evi-
dence that Arg/Citr supplementation may increase systemic NO synthesis in children with SCD.
1. Introduction
NO synthase (NOS) converts L-arginine into equimolar amount of
NO and citrulline [1]. Citrulline is also a precursor for de novo renal
arginine synthesis and, due to a slower hepatic clearance, citrulline
supplementation may effectively increase systemic arginine
concentrations [2]. A reduced nitric oxide (NO) bioavailability is
thought to underlie vascular complications associated with Sickle Cell
Disease (SCD) [3]. Arginine is metabolized by the arginase enzyme to
ornithine which is a competitive inhibitor of arginine uptake by en-
dothelial cells [4]. Clinical conditions associated with excessive hae-
molysis, such as SCD and malaria, are characterized by an excessive
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release of arginase from erythrocytes and consequent reduction of
plasma arginine concentrations (i.e., hypo-argininemia) [2,5,6].
Stable isotopic methods used for the measurement of systemic
whole-body NO synthesis are mostly based on the oral administration
or intravenous infusion of labelled arginine and collection of repeated
blood and urine samples [7]. Less invasive methods to measure NO
availability are based on the measurement of NO metabolites in plasma
(i.e., nitrite, nitrate, cGMP) but the validity and reproducibility of these
biomarkers is limited as results may be confounded by factors such as
dietary nitrate intake, kidney function or sensitivity of analytical
methods [8]. Siervo et al. validated a non-invasive stable isotopic
method to provide a quantitative and more accurate estimate of sys-
temic whole-body NO synthesis in humans (Oral Nitrate Test, ONT) [9].
This method employs a very small oral dose of labelled sodium nitrate
followed by the collection of repeated saliva samples over a period of
18 h [9].
We conducted a pilot study to determine the feasibility of the ONT
isotopic method to measure systemic NO synthesis in a sub-sample of
Tanzanian children with SCD enrolled in the second phase of a random-
order, double-blind, cross-over clinical trial (NCT01718054). A sec-
ondary objective was to determine whether daily supplementation with
a ready-to-use-supplementary food (RUSF) fortified with arginine and
citrulline [RUSF+Arg/Cit] increased systemic NO production com-
pared to children receiving RUSF without Arg/Cit fortification.
2. Methods
Twenty-nine children (70% male, 9–11 years, weight 16.3–31.3 kg)
with SCD were enrolled in this study during the second intervention
phase of the cross-over clinical trial. The study protocol was approved
by the London School of Hygiene and Tropical Medicine and Muhimbili
University of Health and Allied Sciences institutional review boards. All
parents/guardians provided informed consent and all children assented.
Sixteen children received RUSF+Arg/Cit (arginine, 0.2 g/kg/day; ci-
trulline, 0.1 g/kg/day) in combination with daily chloroquine (50 mg)
and thirteen received the base RUSF in combination with weekly
chloroquine (150 mg). Both RUSF formulations provided 500 kcal, 1
RDA of vitamins and minerals & 1 mg of folate (Nutriset, France). The
ONT method measures the decay of an oral dose of labelled sodium
nitrate in serial saliva samples [9]. Briefly, children received a con-
trolled low nitrate meal and a baseline saliva sample was collected 4 h
after the meal. This was followed by the ingestion of an oral dose of
4mg of Na15NO3 (15N, 98% +, Cambridge Isotope Laboratories, Inc.,
Andover, MA, USA) in 100 mL of nitrate-free water. The remaining
samples were collected at 6, 7, 8, 17 and 18 h post-meal. Measurements
of nitrate enrichments in saliva were conducted using Gas Chromato-
graphy Mass Spectrometry as described by Siervo et al. [9]. The isotopic
decay of the oral dose of labelled nitrate was defined by an exponential
function for a single compartment which was employed to calculate the
rate of whole-body NO production [9]. Amino acid concentrations were
measured in frozen lithium heparin plasma samples (Biochrom-30
amino acid analyzer (Biochrom, UK)) at the end of each intervention
period and at baseline entry into the main trial. More detailed de-
scriptions of the ONT and amino acid analyses are provided in the
online supplementary material. Whole-body NO production using the
ONT method was assessed at the end of each intervention phase after a
mean duration of approximately 10.7 weeks. NO production was as-
sessed again after a washout period of approximately 8 weeks (range
5–12 weeks) in both intervention groups (Fig. 1A). The sample size was
calculated using data of NO production measured by the ONT method
in obese subjects with and without metabolic syndrome (3). A sample
size of nine subjects per group was estimated to have 90% power to
detect a difference in whole-body NO production using the ONT method
similar to that observed between obese adults with (0.21 ± 0.13μmol/
hr/kg) and without (0.49 ± 0.22 μmol/h/kg) metabolic syndrome [9].
Mann-Whitney U test was used to assess significant differences in
NO production between the RUSF+Arg/Cit and base RUSF interven-
tion groups. The paired Wilcoxon test was used to assess significant
changes in NO production between supplementation and wash-out
periods within the same intervention group. Analyses were performed
using SPSS 22 for Windows (IBM, USA).
3. Results
Age and sex were not associated with NO production (data not
shown). The RUSF+Arg/Cit intervention significantly increased
plasma arginine, ornithine, non-significantly increased citrulline and
significantly decreased the ratio of asymmetric dimethylarginine
(ADMA) to arginine compared to the base RUSF intervention. The
global arginine bioavailability ratio (GABR; arginine/ornithine+ci-
trulline) and the ratio of arginine to ornithine were not statistically
different between the two interventions (Table 1).
Baseline NO synthesis in children with SCD was 2.32 ± 0.97 μmol/
kg/h. The difference in NO synthesis between the treatment and
washout periods was significant in the RUSF-Arg/Citr group (P= .04)
but not in the RUSF group (P= .80) (Fig. 1B). The isotopic decay of the
stable isotope tracer was characterized by a good linear fit in both
groups; the effect of the interventions on systemic NO production is
described by the differences in isotopic decays in the RUSF (Fig. 1C)
and RUSF+ARG/CIT (Fig. 1D) groups. However, the difference in NO
synthesis between the RUSF-Arg/Citr and RUSF groups at the end of the
intervention was not significant (P= .31). NO synthesis was not cor-
related with citrulline, arginine and ADMA concentrations, and ADMA
to arginine ratio (data not shown).
4. Discussion
The acceptability of the ONT method in children with SCD was
good. This is the first study to report measurements of systemic NO
production in non-hospitalized children with SCD using a non-invasive
stable isotopic method, which may promote further research into the
role of NO in SCD and other conditions characterized by impaired NO
regulation. Baseline NO synthesis rates in children with SCD
(2.32 ± 0.97 μmol/kg/h) were greater than healthy adults
(0.63 ± 0.20 μmol/kg/h) and obese subjects with metabolic syndrome
(0.21 ± 0.13 μmol/kg/h) using the ONT method [9]. The NO synthesis
rates observed in our study were also greater than rates measured in
hospitalized children with uncomplicated malaria using an invasive
method requiring an intravenous administration of labelled 15N-argi-
nine (0.83 ± 0.11 μmol/kg/h; range 0.3–2.65 μmol/kg/h) and collec-
tion of total urine output over a period of 48 h [10]. A lower systemic
NO synthesis was also measured in ten critically ill children with sepsis
(NO synthesis rate= 1.58 ± 0.7 μmol/kg/h) and differences with our
study could be related to disease pathogenesis and/or characteristics of
the stable isotope methods [11]. However, two studies found similar
(2.4 ± 0.6 μmol/kg/h) [12] or higher (4.3 ± 2.7 μmol/kg/h) [13] NO
synthesis rates in adult patients with cirrhosis and end stage renal
disease, respectively, using isotopic methods based on the intravenous
administration of labelled arginine. There is currently limited in-
formation on the NO synthesis rates in pediatric populations. The only
study to evaluate the efficiency of the enzymatic NO synthetic pathway
in children was conducted by Forte et al. [14]. The study used oral
labelled arginine in 17 healthy children aged 4–16 years old to measure
the percentage of L-[15N]2-guanidino arginine dose directed to NO
synthesis but it did not report rates of whole-body NO synthesis. The
study found that the proportion of labelled arginine directed to NO
synthesis was 0.22% and also observed that the percent rate of in-
corporation was inversely associated with age (r=−0.53, p < .05);
we did not observe a similar association between age and NO synthesis
which could be due to the narrower age range of our population.
A previous study has shown that oral supplementation with arginine
and citrulline increases NO synthesis in patients with SCD [15,16] and
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improves NO-mediated endothelial function in adults with impaired
vascular health [17]. The higher NO synthesis observed in our study
suggest that NO synthesis in children with SCD may not be affected by a
reduced availability of arginine and the elevated rate of whole-body NO
synthesis may be the result of compensatory responses to an increased
rate of NO degradation [18,19].
However, this study is characterized by several limitations which
need to be taken into account in the interpretation of the results.
Systemic NO production measured by the ONT method reflects the
contribution of both enzymatic and non-enzymatic NO synthetic path-
ways; however, the controlled low nitrate diet followed by the children
as part of the ONT protocol was implemented to reduce the contribu-
tion of the non-enzymatic pathway [20]. In addition, there is currently
no evidence on the effects of arginine, citrulline and nitrate supple-
mentation on the efficiency of bacterial and tissue nitrate reductase
activity and therefore the impact of these nutrients and drug on the rate
of conversion of nitrate into NO via the non-enzymatic synthetic
pathways is undetermined. It is also important to highlight that an in-
crease in NO synthesis and overall bio-availability does not necessarily
correspond to an increased NO-mediated activation of cellular me-
chanisms. It is possible that the observed increase in systemic NO
production in the RUSF-Arg/Cit group was the result of the higher dose
of chloroquine in this group, rather than from a greater supply of
Fig. 1. A: Study design. Figure summarises the oral nitrate test (ONT) method used to measure nitric oxide synthesis and the time points of sample collection from children in the 2nd
phase of the V-FIT cross-over trial. B Differences in whole body NO synthesis measured using the ONT between supplemented (RUSF+Arg/Citr in combination with daily chloroquine
[50 mg]) and non-supplemented arms (base RUSF in combination with weekly chloroquine [150 mg]) during the intervention and wash out period. Data presented as mean± SEMs and
P-values from paired Wilcoxan tests for non-parametric data. C and D shows the time-course of the isotopic disappearance of the tracer, expressed as tracer-tracee ratio, followed for 14 h
after the administration of an oral dose of labelled sodium nitrate (Na15NO3). The mean values of the tracer-tracee ratio for the saliva kinetic curves are reported on a semi-logarithmic
scale and shown for the base RUSF (Fig. 1C) and RUSF+Arg/Citr (Fig. 1D) arms.
Table 1
Age, sex, weight and plasma amino acid concentrations involved in nitric oxide synthesis
in the two groups of children during intervention either with RUSF+ARG/CIT or stan-
dard RUSF.
RUSF+ARG/CITR RUSF Pa
N 16 13
Age (years) 11.06 ± 1.23 11.30 ± 1.25 0.68
Gender (M/F) 13/3 7/6 0.11
Weight (kg) 24.61 ± 3.52 25.18 ± 3.43 0.75
Arginine (nmol/mL) 130.16 ± 115.65 62.11 ± 15.58 0.02
Ornithine (nmol/mL) 101.05 ± 71.00 52.33 ± 12.81 0.003
Citrulline (nmol/mL) 48.19 ± 62.66 22.18 ± 6.02 0.07
ADMA (nmol/mL) 0.95 ± 0.25 0.96 ± 0.24 0.84
Arginine/Ornithine Ratio 1.22 ± 0.35 1.20 ± 0.23 0.89
ADMA/Arginine Ratio 0.011 ± 0.007 0.016 ± 0.006 0.01
GABR 0.86 ± 0.23 0.84 ± 0.17 0.49
Data are presented as mean± SD. N = number of subjects; M = Male; F = Female.
ADMA = asymmetric dimethylarginine. RUSF = ready-to-use supplementary food. ARG
= arginine; CITR = citrulline; GABR=Global arginine bioavailability ratio. Mann-
Whitney test was used to compare the two intervention groups.
a P value is for comparison of the two intervention groups.
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arginine from the fortificants, which may have reduced arginase ac-
tivity [21] and/or inflammation [22,23] and result in greater NO
bioavailability in children with SCD [24]. However, there was no dif-
ference in the arginine:ornithine ratio between the two groups and
therefore a different degree of inhibition of arginase activity by chlor-
oquine administration seems unlikely. In addition, weekly doses of
chloroquine in the RUSF group did not have an effect on NO synthesis.
While we found a decrease in the ADMA to arginine ratio between the
two intervention groups, the within-intervention changes of the ratio
were not different between the two groups, which, if added to a lack of
significant correlation of the ADMA to arginine ratio with whole-body
NO production, seems to suggest that ADMA was not linked to the in-
crease in NO synthesis. Finally, a comparison of systemic NO produc-
tion rates measured in children with SCD and age-matched healthy
controls should be investigated in future studies.
The application of the non-invasive isotopic method for the mea-
surement of systemic NO production is feasible in this population and
our results suggest that supplementation with arginine and citrulline
may increase NO synthesis in children with SCD, although it is unclear
by what mechanism.
5. Trial registration
V-FIT is registered on clinicaltrials.gov with ID number
NCT01718054.
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